Qtrilmet
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Metformin hydrochloride;saxagliptin;dapagliflozin
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control. when already being treated with metformin and saxagliptin and dapagliflozin.
From the official label · 2026-09-30 · European Medicines Agency
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (metformin hydrochloride). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-01
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Metformin hydrochloride;saxagliptin;dapagliflozin |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10BD · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2019-11-11 |
| Last updated by the regulator | 2020-10-09 |
| EMA product number | EMEA/H/C/004910 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).